ReviewCellular & molecular immunology2021
HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy.
Review in Cellular & molecular immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 2 syntheses or guidelines pooled it, 103 citations in OpenAlex.
- Epigenetic regulation of major histocompatibility complexes in gastrointestinal malignancies and the potential for clinical interception.Clinical epigenetics · 2024Pooled it
- Prognostic and Clinical Significance of Human Leukocyte Antigen Class I Expression in Breast Cancer: A Meta-Analysis.Molecular diagnosis & therapy · 2023Pooled it
- Resolving cell-cell interaction networks and their molecular logic in complex tissues.Nature methods · 2026Article
- Heterogeneity in cancer: molecular mechanisms and therapeutic strategies.Signal transduction and targeted therapy · 2026Review
- TAP1 deficiency reshapes tumor antigenicity and enables CD8 T cell targeting in colorectal cancer.Molecular therapy. Oncology · 2026Article
- Review
- Predictors of Immune Checkpoint Blockade Response in dMMR Colorectal Cancer Using an Integrated Immune-Enhanced Multiomics Platform.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Techniques to study chimerism at the tissue level in humanized mice.Veterinary pathology · 2026Article
- Single-cell and spatial transcriptome profiling identifies cellular heterogeneity and immunosuppressive tumor microenvironment in inflammatory breast cancer.Journal of advanced research · 2026Article
- Cathepsin-D-mediated MHC class I degradation contributes to immune evasion in colorectal cancer.Cell reports. Medicine · 2026Article
- Primary pulmonary histiocytic sarcoma with CNS metastasis: a case report and molecular profiling insights.Frontiers in oncology · 2026Article
- Article
- Comprehensive Review of Immunotherapy in Colorectal Cancer: From Mechanisms to Nursing Interventions.ImmunoTargets and therapy · 2026Review
- Characterisation of tumor-infiltrating gamma-delta T cells in human colorectal cancer with MHC-I loss.Clinical & translational immunology · 2026Article
- The immune microenvironment of colorectal cancer.Nature reviews. Cancer · 2025Review
- Review
- A novel spatial framework to validate arsenic exposure gene expression profiling in bladder cancer using multiplex FISH and AI-powered digital pathology.Scientific reports · 2025Article
- Adipose-tumor crosstalk in colorectal cancer: Identifying (Epi)genetic biomarkers for tumor progression and cachexia.Cell death & disease · 2025Article
- Unleashing NK cells for cancer immunotherapy in lung cancer: biologic challenges and clinical advances.Journal of experimental & clinical cancer research : CR · 2025Review
- Computed tomography radiomics to predict microsatellite instability status and immunotherapy response in gastric cancer.Insights into imaging · 2025Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
T cell-mediated immune therapies have emerged as a promising treatment modality in different malignancies including colorectal cancer (CRC). However, only a fraction of patients currently respond to treatment. Understanding the lack of responses and finding biomarkers with predictive value is of great importance. There is evidence that CRC is a heterogeneous disease and several classification systems have been proposed that are based on genomic instability, immune cell infiltration, stromal content and molecular subtypes of gene expression. Human leukocyte antigen class I (HLA-I) plays a pivotal role in presenting processed antigens to T lymphocytes, including tumour antigens. These molecules are frequently lost in different types of cancers, including CRC, resulting in tumour immune escape from cytotoxic T lymphocytes during the natural history of cancer development. The aim of this review is to (i) summarize the prevalence and molecular mechanisms behind HLA-I loss in CRC, (ii) discuss HLA-I expression/loss in the context of the newly identified CRC molecular subtypes, (iii) analyze the HLA-I phenotypes of CRC metastases disseminated via blood or the lymphatic system, (iv) discuss strategies to recover/circumvent HLA-I expression/loss and finally (v) review the role of HLA class II (HLA-II) in CRC prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.